Literature DB >> 25797499

Neurobiological background of negative symptoms.

Silvana Galderisi1, Eleonora Merlotti2, Armida Mucci2.   

Abstract

Studies investigating neurobiological bases of negative symptoms of schizophrenia failed to provide consistent findings, possibly due to the heterogeneity of this psychopathological construct. We tried to review the findings published to date investigating neurobiological abnormalities after reducing the heterogeneity of the negative symptoms construct. The literature in electronic databases as well as citations and major articles are reviewed with respect to the phenomenology, pathology, genetics and neurobiology of schizophrenia. We searched PubMed with the keywords "negative symptoms," "deficit schizophrenia," "persistent negative symptoms," "neurotransmissions," "neuroimaging" and "genetic." Additional articles were identified by manually checking the reference lists of the relevant publications. Publications in English were considered, and unpublished studies, conference abstracts and poster presentations were not included. Structural and functional imaging studies addressed the issue of neurobiological background of negative symptoms from several perspectives (considering them as a unitary construct, focusing on primary and/or persistent negative symptoms and, more recently, clustering them into factors), but produced discrepant findings. The examined studies provided evidence suggesting that even primary and persistent negative symptoms include different psychopathological constructs, probably reflecting the dysfunction of different neurobiological substrates. Furthermore, they suggest that complex alterations in multiple neurotransmitter systems and genetic variants might influence the expression of negative symptoms in schizophrenia. On the whole, the reviewed findings, representing the distillation of a large body of disparate data, suggest that further deconstruction of negative symptomatology into more elementary components is needed to gain insight into underlying neurobiological mechanisms.

Entities:  

Keywords:  Deficit schizophrenia; Genetic; Negative symptoms; Neuroimaging; Neurotransmissions; Persistent negative symptoms

Mesh:

Substances:

Year:  2015        PMID: 25797499     DOI: 10.1007/s00406-015-0590-4

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  227 in total

1.  Ten year progressive ventricular enlargement in schizophrenia: an MRI morphometrical study.

Authors:  T Saijo; T Abe; Y Someya; T Sassa; Y Sudo; T Suhara; T Shuno; K Asai; Y Okubo
Journal:  Psychiatry Clin Neurosci       Date:  2001-02       Impact factor: 5.188

2.  A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography.

Authors:  Steven G Potkin; Gustavo Alva; Kirsten Fleming; Ravi Anand; David Keator; Danilo Carreon; Michael Doo; Yi Jin; Joseph C Wu; James H Fallon
Journal:  Am J Psychiatry       Date:  2002-02       Impact factor: 18.112

3.  A magnetic resonance imaging study of schizophrenia: brain structure and clinical symptoms.

Authors:  A H Young; D H Blackwood; H Roxborough; J K McQueen; M J Martin; D Kean
Journal:  Br J Psychiatry       Date:  1991-02       Impact factor: 9.319

4.  Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia.

Authors:  Alice Egerton; Stefan Brugger; Marie Raffin; Gareth J Barker; David J Lythgoe; Philip K McGuire; James M Stone
Journal:  Neuropsychopharmacology       Date:  2012-07-04       Impact factor: 7.853

5.  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

Authors:  Y Okubo; T Suhara; K Suzuki; K Kobayashi; O Inoue; O Terasaki; Y Someya; T Sassa; Y Sudo; E Matsushima; M Iyo; Y Tateno; M Toru
Journal:  Nature       Date:  1997-02-13       Impact factor: 49.962

6.  Positive and negative symptoms and regional cerebral perfusion in antipsychotic-naive schizophrenic patients: a high-resolution SPECT study.

Authors:  S K Min; S K An; D I Jon; J D Lee
Journal:  Psychiatry Res       Date:  1999-06-30       Impact factor: 3.222

7.  Patterns of cranial, brain and sulcal CSF volumes in male and female deficit and nondeficit patients with schizophrenia.

Authors:  Celso Arango; Robert P McMahon; David M Lefkowitz; Godfrey Pearlson; Brian Kirkpatrick; Robert W Buchanan
Journal:  Psychiatry Res       Date:  2008-01-16       Impact factor: 3.222

8.  Reduced anterior cingulate gray matter volume and thickness in subjects with deficit schizophrenia.

Authors:  Mizuho Takayanagi; Jacqueline Wentz; Yoichiro Takayanagi; David J Schretlen; Elvan Ceyhan; Lei Wang; Michio Suzuki; Akira Sawa; Patrick E Barta; J Tilak Ratnanather; Nicola G Cascella
Journal:  Schizophr Res       Date:  2013-09-12       Impact factor: 4.939

9.  A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.

Authors:  Jeffrey A Lieberman; Geoffrey Dunbar; Anthony C Segreti; Ragy R Girgis; Frances Seoane; Jessica S Beaver; Naihua Duan; David A Hosford
Journal:  Neuropsychopharmacology       Date:  2012-12-18       Impact factor: 7.853

10.  White matter alterations in deficit schizophrenia.

Authors:  Laura M Rowland; Elena A Spieker; Alan Francis; Peter B Barker; William T Carpenter; Robert W Buchanan
Journal:  Neuropsychopharmacology       Date:  2008-12-03       Impact factor: 7.853

View more
  29 in total

1.  Negative symptoms and therapy strategies in schizophrenia.

Authors:  Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-10       Impact factor: 5.270

2.  Association between RGS4 variants and psychotic-like experiences in nonclinical individuals.

Authors:  Marta de Castro-Catala; Paula Cristóbal-Narváez; Thomas R Kwapil; Tamara Sheinbaum; Elionora Peña; Neus Barrantes-Vidal; Araceli Rosa
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-02-24       Impact factor: 5.270

3.  New aspects of the vulnerability stress model in general, its relevance in schizophrenic psychoses and the place of antipsychotics.

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-09       Impact factor: 5.270

Review 4.  Understanding Antipsychotic Drug Treatment Effects: A Novel Method to Reduce Pseudospecificity of the Positive and Negative Syndrome Scale (PANSS) Factors.

Authors:  Seth C Hopkins; Ajay Ogirala; Antony Loebel; Kenneth S Koblan
Journal:  Innov Clin Neurosci       Date:  2017-12-01

5.  Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia.

Authors:  Sarah A Eisenstein; Ryan Bogdan; Ling Chen; Stephen M Moerlein; Kevin J Black; Joel S Perlmutter; Tamara Hershey; Deanna M Barch
Journal:  J Psychiatr Res       Date:  2016-11-17       Impact factor: 4.791

6.  Negative symptoms, anxiety, and depression as mechanisms of change of a 12-month trial of assertive community treatment as part of integrated care in patients with first- and multi-episode schizophrenia spectrum disorders (ACCESS I trial).

Authors:  Stefanie J Schmidt; Matthias Lange; Daniel Schöttle; Anne Karow; Benno G Schimmelmann; Martin Lambert
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-05-24       Impact factor: 5.270

Review 7.  Primary, Enduring Negative Symptoms: An Update on Research.

Authors:  Brian Kirkpatrick; Armida Mucci; Silvana Galderisi
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

8.  Bipolar disorder risk gene FOXO6 modulates negative symptoms in schizophrenia: a neuroimaging genetics study.

Authors:  Joseph J Shenker; Sarojini M Sengupta; Ridha Joober; Ashok Malla; M Mallar Chakravarty; Martin Lepage
Journal:  J Psychiatry Neurosci       Date:  2017-05       Impact factor: 6.186

9.  Prefrontal Transcranial Direct Current Stimulation for Treatment of Schizophrenia With Predominant Negative Symptoms: A Double-Blind, Sham-Controlled Proof-of-Concept Study.

Authors:  Ulrich Palm; Daniel Keeser; Alkomiet Hasan; Michael J Kupka; Janusch Blautzik; Nina Sarubin; Filipa Kaymakanova; Ina Unger; Peter Falkai; Thomas Meindl; Birgit Ertl-Wagner; Frank Padberg
Journal:  Schizophr Bull       Date:  2016-04-20       Impact factor: 9.306

10.  Serum BDNF Is Positively Associated With Negative Symptoms in Older Adults With Schizophrenia.

Authors:  Sasha S Binford; Erin M Hubbard; Elena Flowers; Bruce L Miller; Heather Leutwyler
Journal:  Biol Res Nurs       Date:  2017-10-19       Impact factor: 2.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.